Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2018
At a glance
- Drugs Binimetinib (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 May 2018 Status changed from suspended to recruiting.
- 28 Feb 2018 Status changed from recruiting to suspended.